Publication:
Relationship of visceral adipose tissue with surrogate insulin resistance and liver markers in individuals with metabolic syndrome chronic complications

dc.contributor.authorBullon-Vela, Vanessa
dc.contributor.authorAbete, Itziar
dc.contributor.authorTur, Josep A
dc.contributor.authorKonieczna, Jadwiga
dc.contributor.authorRomaguera, Dora
dc.contributor.authorPinto, Xavier
dc.contributor.authorCorbella, Emili
dc.contributor.authorMartinez-Gonzalez, Miguel A
dc.contributor.authorSayon-Orea, Carmen
dc.contributor.authorToledo, Estefanía
dc.contributor.authorCorella, Dolores
dc.contributor.authorMacias-Gonzalez, Manuel
dc.contributor.authorTinahones, Francisco J
dc.contributor.authorFito, Montserrat
dc.contributor.authorEstruch, Ramon
dc.contributor.authorRos, Emilio
dc.contributor.authorSalas-Salvado, Jordi
dc.contributor.authorDaimiel, Lidia
dc.contributor.authorMascaró, Catalina M
dc.contributor.authorZulet, Maria Angeles
dc.contributor.authorMartinez, Jose Alfredo
dc.contributor.authorPREDIMED-Plus Investigators
dc.date.accessioned2024-09-13T09:15:57Z
dc.date.available2024-09-13T09:15:57Z
dc.date.issued2020-10
dc.description.abstractBackground: Visceral adipose tissue (VAT) has a hazardous influence on systemic inflammation, insulin resistance and an adverse metabolic profile, which increases the risk of developing non-alcoholic fatty liver disease (NAFLD) and chronic complications of diabetes. In our study we aimed to evaluate the association of VAT and the triglyceride glucose (TyG) as a proxy of insulin resistance surrogated with metabolic and liver risk factors among subjects diagnosed with metabolic syndrome (MetS). Methods: A cross-sectional study was performed including 326 participants with MetS (55-75 years) from the PREDIMED-Plus study. Liver-status markers, VAT and TyG were assessed. Participants were stratified by tertiles according to VAT (n = 254) and TyG (n = 326). A receiver operating characteristic curve was used to analyse the efficiency of TyG for VAT. Results: Subjects with greater visceral fat depots showed worse lipid profile, higher homeostatic model assessment for insulin resistance (HOMA-IR), TyG, alanine transaminase (ALT), fibroblast growth factor-21 (FGF-21), fatty liver index (FLI) and hepatic steatosis index (HSI) compared with participants in the first tertile. The multi-adjusted linear-regression analyses indicated that individuals in the third tertile of TyG (>9.1-10.7) had a positive association with HOMA-IR [beta = 3.07 (95% confidence interval (CI) 2.28-3.86; p trend < 0.001)], ALT [beta = 7.43 (95% CI 2.23-12.63; p trend = 0.005)], gamma glutamyl transferase (GGT) [beta = 14.12 (95% CI 3.64-24.61; p trend = 0.008)], FGF-21 [beta = 190.69 (95% CI 93.13-288.25; p trend < 0.001)], FLI [beta = 18.65 (95% CI 14.97-22.23; p trend < 0.001)] and HSI [beta = 3.46 (95% CI, 2.23-4.68; p trend < 0.001)] versus participants from the first tertile. Interestingly, the TyG showed the largest area under the receiver operating curve (AUC) for women (AUC = 0.713; 95% CI 0.62-0.79) compared with men (AUC = 0.570; 95% CI 0.48-0.66). Conclusions: A disrupted VAT enlargement and impairment of TyG are strongly associated with liver status and cardiometabolic risk factors linked with NAFLD in individuals diagnosed with MetS. Moreover, the TyG could be used as a suitable and reliable marker estimator of VAT.en
dc.description.sponsorshipThe authors disclose receipt of the following financial support for the research, authorship, and/or publication of this article: the PREDIMED-Plus trial was supported by the European Research Council (Advanced Research grant 2014-2019; agreement #340918; granted to Dr MartinezGonzalez); the official Spanish institutions for funding scientific biomedical research, CIBER Fisiopatologia de la Obesidad y Nutricion (CIBERobn) and Instituto de Salud Carlos III (ISCIII) through the Fondo de Investigacion para la Salud (FIS) that is co-funded by the European Regional Development Fund (coordinated FIS projects led by Drs Salas-Salvado and Vidal, including the following projects: PI13/00673, PI13/00492, PI13/00272, PI13/01123, PI13/00462, PI13/00233, PI13/02184, PI13/00728, PI13/01090, PI13/01056, PI14/01722, PI14/00636, PI14/00618, PI14/00696, PI14/01206, PI14/01919, PI14/00853, PI14/01374, PI14/00972, PI14/00728, PI14/01471, PI16/00473, PI16/00662, PI16/01873, PI16/01094, PI16/00501, PI16/00533, PI16/00381, PI16/00366, PI16/01522, PI16/01120, PI17/00764, PI17/01183, PI17/00855, PI17/01347, PI17/00525, PI17/01827, PI17/00532, PI17/00215, PI17/01441, PI17/00508, PI17/01732, PI17/00926, PI19/00957, PI19/00386, PI19/00309, PI19/01032, PI19/00576, PI19/00017, PI19/01226, PI19/00781, PI19/01560, PI19/01332) and the Especial Action Project 'Implementacion y evaluacion de una intervencion intensiva sobre la actividad fisica Cohorte PREDIMED-Plus' (Dr Salas-Salvado); the Recercaixa (grant number 2013ACUP00194) (Dr Salas-Salvado); J. Salas-Salvado, gratefully acknowledges the financial suuport by ICREA under the ICREA Academia program; the SEMERGEN grant; International Nut and Dried Fruit Council-FESNAD (Long-term effects of an energy-restricted Mediterranean diet on mortality and cardiovascular disease 2014-015; no. 201302; Dr Martinez-Gonzalez); the AstraZeneca Young Investigators Award in Category of Obesity and T2D 2017 (Dr Romaguera); grants from the Consejeria de Salud de la Junta de Andalucia (PI0458/2013; PS0358/2016; PI0137/2018), the PROMETEO/2017/017 grant from the Generalitat Valenciana, the SEMERGEN grant; grant of support to research groups 35/2011 (Balearic Islands Gov; FEDER funds; Drs Tur and Bouz). JK is contracted for the `FOLIUM' programme within the FUTURMed project. Talent for the medicine within the future from the Fundacion Instituto de Investigacion Sanitaria Illes Balears (financed by 2017 annual plan of the sustainable tourism tax and at 50% with charge to the ESF Operational Programme 2014-2020 of the Balearic Islands). CMM received an FPU grant from the Ministry of Education, Spain. VB-V received a grant from the Centre for Nutrition Research of the University of Navarra.es_ES
dc.format.page1_15es_ES
dc.format.volume11es_ES
dc.identifier.citationBullon-Vela V, Abete I, Tur JA, Konieczna J, Romaguera D, Pinto X, et al. Relationship of visceral adipose tissue with surrogate insulin resistance and liver markers in individuals with metabolic syndrome chronic complications. Ther Adv Endocrinol Metab. 2020 Oct;11:1-15.en
dc.identifier.doi10.1177/2042018820958298
dc.identifier.e-issn2042-0196es_ES
dc.identifier.issn2042-0188
dc.identifier.journalTherapeutic Advances in Endocrinology and Metabolismes_ES
dc.identifier.otherhttp://hdl.handle.net/20.500.13003/9225
dc.identifier.pubmedID33149882es_ES
dc.identifier.puiL2007069843
dc.identifier.scopus2-s2.0-85093933092
dc.identifier.urihttps://hdl.handle.net/20.500.12105/23034
dc.identifier.wos586583200001
dc.language.isoengen
dc.publisherSAGE Publishing
dc.relation.publisherversionhttps://dx.doi.org/10.1177/2042018820958298en
dc.rights.accessRightsopen accessen
dc.rights.licenseAttribution-NonCommercial 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectInsulin resistance
dc.subjectMetabolic syndrome
dc.subjectnon-alcoholic fatty liver disease
dc.subjectTriglyceride glucose index
dc.subjectVisceral adipose tissue
dc.titleRelationship of visceral adipose tissue with surrogate insulin resistance and liver markers in individuals with metabolic syndrome chronic complicationsen
dc.typeresearch articleen
dspace.entity.typePublication
relation.isPublisherOfPublicationdfa013d1-54c0-41b6-acc8-4fea39092dc7
relation.isPublisherOfPublication.latestForDiscoverydfa013d1-54c0-41b6-acc8-4fea39092dc7

Files